{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-233375","form_type":"8-K","ticker":"COAG","cik":"0002114044","company_name":"Hemab Therapeutics Holdings, Inc.","filed_at":"2026-05-21T11:05:12+00:00","discovered_at":"2026-05-21T11:10:00.335711+00:00","generated_at":"2026-05-21T11:13:37.365237+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Hemab reports Q1 net loss $22.7M; completes $346.7M IPO, gets BTD for sutacimig","bullets":["Net loss Q1 2026: $22.7M ($23.98/share) vs $15.3M ($16.18/share) YoY.","Cash $163.5M at March 31; with $317.2M net IPO proceeds, runway into 2029.","Completed IPO in May 2026: 19.26M shares at $18.00, raising $346.7M gross; now listed on Nasdaq under COAG.","FDA granted Breakthrough Therapy Designation for sutacimig in Glanzmann thrombasthenia in March 2026.","Preparing Phase 3 pivotal trial for sutacimig in GT expected H2 2026; data from Factor VII and VWD trials in late 2026/early 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-233375","json":"https://secwatch.observer/filing/0001193125-26-233375.json","markdown":"https://secwatch.observer/filing/0001193125-26-233375.md","text":"https://secwatch.observer/filing/0001193125-26-233375.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2114044/000119312526233375/0001193125-26-233375-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2114044/000119312526233375/d102408d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T11:13:37.365237+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"12b46a0d5c894009c411284e505abdd8d6d3a307","claim":"Hemab Therapeutics Holdings, Inc. reported the first quarter ended March 31, 2026 results: net income $22.7 million, or $23.98 per share, EPS $23.98 per share.","evidence_excerpt":"Hemab Therapeutics Holdings, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended March 31, 2026.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/2114044/000119312526233375/0001193125-26-233375-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2026"},{"label":"Net income","value":"$22.7 million, or $23.98 per share"},{"label":"EPS","value":"$23.98 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}